Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
MWN-AI** Summary
Immutep Limited has announced promising progress from its first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody designed to address autoimmune diseases by modulating T-cell activity. According to the company's update on March 19, 2026, the single ascending dose (SAD) phase of the study has been completed successfully. IMP761 was well tolerated at all tested dose levels, reaching up to 14 mg/kg, with no safety concerns or dose-limiting toxicities reported thus far. The study has now transitioned to the multiple ascending dose (MAD) portion, which is assessing pharmacokinetics and safety across two doses, with completion expected in the third quarter of 2026.
Dr. Frédéric Triebel, Chief Scientific Officer at Immutep, noted that the initial findings highlight IMP761’s ability to exert a clear immunosuppressive effect in healthy participants, demonstrating durable inhibition of T-cell mediated responses following administration. This positions the therapy as a potential approach to selectively silence pathogenic, self-antigen-specific memory T cells, with future testing proposed in a Phase II trial targeting patients with autoimmune conditions.
IMP761's mechanism focuses on enhancing the inhibitory function of LAG-3, aiming to restore immune balance in diseases like rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis. By specifically targeting LAG-3 expressing T cells at disease sites, IMP761 promises a more precise therapeutic option with potentially reduced adverse effects compared to traditional treatments. The full Phase I data will be shared at the European Alliance of Associations for Rheumatology (EULAR) conference on June 4, 2026, indicating Immutep's commitment to advancing novel immunotherapies for unmet medical needs.
MWN-AI** Analysis
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has released promising results from its Phase I study of IMP761, a first-in-class LAG-3 agonist aimed at treating autoimmune diseases. With the successful completion of the single ascending dose (SAD) portion demonstrating good tolerability and no safety issues up to 14 mg/kg, investor sentiment should remain cautiously optimistic as the company progresses into the multiple ascending dose (MAD) phase. The upcoming presentation of these findings at the EULAR conference on June 4, 2026, will provide a critical opportunity for further validation among the scientific community and potential investors.
LAG-3 agonists hold considerable promise due to their mechanism of action, selectively targeting dysregulated T cells implicated in autoimmune diseases like rheumatoid arthritis and Type 1 diabetes. These markets are notable for their multi-billion-dollar potential, making the success of IMP761 pivotal to Immutep’s growth trajectory. Given the well-tolerated profile of IMP761 established in early trials, the company is well-positioned to capitalize on its therapeutic applications, and the specificity of LAG-3 expression on activated T cells suggests that IMP761 could offer a targeted approach with fewer adverse effects compared to existing treatments.
Investors should closely monitor the progress of the MAD phase, expected to conclude in Q3 2026, along with the responses at the EULAR conference. Positive results from these phases could significantly enhance the company's market valuation. However, given the inherent risks in clinical trials and the competitive nature of immunotherapy, prudent investors may wish to weigh market enthusiasm against overall company fundamentals and pipeline developments to make informed decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Immutep has completed the single ascending dose (SAD) portion of its IMP761 study
- IMP761 was well tolerated across all dose levels
- IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026
SYDNEY, AUSTRALIA, March 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody which enhances the physiological inhibitory function of LAG-3 on T-cell receptor signaling, potentially suppressing pathogenic T cell responses in autoimmune diseases.
The Company reported that the single ascending dose (SAD) portion of the study has been successfully completed, with dosing up to 14 mg/kg. IMP761 was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed to date.
The study is currently progressing in the multiple ascending dose (MAD) portion, which is evaluating pharmacokinetics and safety across two dose levels. Completion of the MAD portion is expected in the third quarter of 2026.
“IMP761 continues to show a clear immunosuppressive effect in healthy participants challenged with a foreign antigen in an intra-dermal reaction, with durable inhibition of T-cell–mediated responses after a single administration,” said Dr Frédéric Triebel, Chief Scientific Officer, Immutep. “These first-in-human findings support our mechanistic aim of selectively silencing pathogenic, self-antigen–specific memory T cells via LAG--3 agonism and provide the basis for dose levels to be tested in a future phase II trial in patients with autoimmunity.”
IMP761 data, including Phase I results, will be presented at the European Alliance of Associations for Rheumatology (EULAR) annual congress in London, UK on 4th June 2026 at 1.30 pm UK time in a poster view session.
A LAG-3 agonist represents a novel therapeutic approach aimed at restoring immune tolerance by modulating T-cell activity, with potential applications across a range of autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis. IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large, increasingly prevalent disorders, each of which represent multi-billion-dollar markets.
By enhancing the physiological “brake” function of LAG-3 to silence dysregulated self-antigen-specific memory T cells, IMP761 is designed to target the cause of autoimmune diseases and restore balance to the immune system. LAG-3 expression on activated T cells demonstrates high specificity for disease sites, especially in tissues characterised by chronic inflammation. This distinct characteristic of the LAG-3 immune checkpoint suggests IMP761 may enable a more targeted therapeutic approach with fewer adverse effects compared to other treatments.
About IMP761
IMP761, a first-in-class immunosuppressive lymphocyte-activation gene-3 (LAG-3) agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the immune system. Encouraging pre-clinical in vivo and in vitro studies show IMP761 inhibits peptide-induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction.1 Additional preclinical data in oligoarticular juvenile idiopathic arthritis details how IMP761 led to a decrease in 48 hours in a broad spectrum of effector cytokines in coculture experiments where patients T cells are mixed with autologous synoviocytes.2 Similarly, IMP761 decreased IFN?, interleukin-4, and tumor necrosis factor ? levels in supernatants from cocultures of T cells from patients with systemic sclerosis with their autologous dermal fibroblasts.3
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Investors/Media:
Matthew Beck, astr partners
Ph: +1 (917) 415-1750; matthew.beck@astrpartners.com
1 Angin M, Brignone C, Triebel F. A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced
Autoimmune Diseases. J Immunol. 2020 15;204:810-818.
2 Sag E, Demir S, Aspari M, Nielsen MA, Skejø C, Hvid M, Turhan E, Bilginer Y, Greisen S, Ozen S, Deleuran
B. Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with
oligoarticular subtypes. Pediatr Res. 2021;90:744-751.
3 Aspari, M., Greisen, S., Hvid, M., Ong, V.H., Denton, C.P., Abraham, D. and Deleuran, B. Lymphocyte
Activation Gene 3 Regulation of Profibrotic Cytokines and Type I Collagen Production in Patients With
Systemic Sclerosis. ACR Open Rheumatology, 2026 8: e70120.
FAQ**
What are the anticipated outcomes for the multiple ascending dose (MAD) portion of the IMP761 study, and how does Immutep Limited IMMP plan to address any challenges that may arise during this phase?
How does the successful completion of the single ascending dose (SAD) portion support Immutep Limited IMMP's future phase II trial goals for IMP761 in treating autoimmune diseases?
What specific autoimmune diseases does Immutep Limited IMMP aim to target with IMP761, and what is the projected market size for these conditions?
Can you elaborate on the potential advantages of using IMP761, a LAG-3 agonist, over existing treatments for autoimmune diseases from the perspective of Immutep Limited IMMP?
**MWN-AI FAQ is based on asking OpenAI questions about Immutep Limited (NASDAQ: IMMP).
NASDAQ: IMMP
IMMP Trading
-3.9% G/L:
$0.3152 Last:
318,377 Volume:
$0.3215 Open:
